Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. Caniglia EC, et al. Among authors: abgrall s. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):214-21. doi: 10.1097/QAI.0000000000000956. J Acquir Immune Defic Syndr. 2016. PMID: 26895294 Free PMC article.
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Kousignian I, et al. Among authors: abgrall s. J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7. doi: 10.1097/00126334-200309010-00007. J Acquir Immune Defic Syndr. 2003. PMID: 14501793
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Clin Infect Dis. 2003 Dec 1;37(11):1517-26. doi: 10.1086/379070. Epub 2003 Oct 29. Clin Infect Dis. 2003. PMID: 14614675
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Abgrall S, et al. Clin Infect Dis. 2007 Jan 1;44(1):120-7. doi: 10.1086/509578. Epub 2006 Nov 16. Clin Infect Dis. 2007. PMID: 17143827
Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4). Selinger-Leneman H, et al. Among authors: abgrall s. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-11. doi: 10.1097/QAI.0b013e31815aca91. J Acquir Immune Defic Syndr. 2008. PMID: 17971717
199 results